Amgen/UCB's romosozumab writes script for osteoporosis sequel
This article was originally published in Scrip
Executive Summary
Amgen and UCB's investigational sclerostin inhibitor, romosozumab, can produce increases in bone mineral density (BMD) significantly greater than those seen with the older osteoporosis treatments Fosamax (alendronate sodium) and Lilly's Forteo/Forsteo (teriparatide), exploratory analyses of Phase II data suggest. One commentator has suggested that as long as Phase III studies translate the early promise into antifracture efficacy and confirm long-term safety, romosozumab may represent "a sequel to the anabolic story" more than a decade after the introduction of teriparatide.